ENG/中
老虎证券
行情
产品介绍
Cash Boost账户
美股
美股碎股
港股
A股通
期权
期货
美国国债
定投
固定票息票据
Tiger BOSS Debit Card
基金超市
老虎钱袋子
老虎API平台
Wealth
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
专栏
TigerAI
机构
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
登录
立即注册
Toggle
美股
详情
本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务
Aegerion制药
1.97
+0.0000
成交量:
- -
成交额:
- -
市值:
5,820.38万
市盈率:
-0.33
高:
1.97
开:
1.97
低:
1.97
收:
1.97
数据加载中...
总览
公司
新闻
公告
公司资料
公司名字:
Aegerion制药
交易所:
NASDAQ
成立时间:
- -
员工人数:
- -
公司地址:
- -
官网:
http://www.aegerion.com
邮编:
- -
电话:
- -
传真:
- -
简介:
Aegerion Pharmaceuticals, Inc.是一家生物制药公司,致力于为那些衰弱的、患有致命罕见疾病的人开发新奇的,并且能够挽救生命的治疗方法并将其用于商业用途。公司的第一个产品JUXTAPID,在2012年12月21日得到了美国食品和药物管理局的营销批准,并作为对低脂肪饮食和其他降脂治疗的补充,包括低密度脂蛋白(LDL)血清法,如果可用,可降低纯合子家族性高胆固醇血症患者(HoFH)的低密度脂蛋白胆固醇(低密度)、总胆固醇(TC)、载脂蛋白B(B朊)和非高密度脂蛋白胆固醇(non-HDL-C)。2013年1月底,该公司在美国推出了JUXTAPID。在2012年的第一季度,它向欧洲药品局(EMA)提交了营销授权申请(MAA)请求批准上市,作为低脂肪饮食和其他降脂治疗的辅助,在用或是不用血清法的条件下减少患有血症的成年人体内的低密度脂蛋白、TC、载脂蛋白B和甘油三酯(TG)。公司于2005年2月在特拉华州法律下成立。
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/AEGR/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AEGR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AEGR\",,,,,undefined,":{"symbol":"AEGR","market":"US","secType":"STK","nameCN":"Aegerion制药","latestPrice":1.97,"timestamp":1480539600000,"preClose":1.97,"halted":0,"volume":0,"delay":0,"floatShares":14289727,"shares":29545088,"eps":-5.97,"marketStatus":"休市中","change":0,"latestTime":"11-30 16:00:00 EST","open":1.97,"high":1.97,"low":1.97,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.97,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1746432000000},"marketStatusCode":7,"adr":0,"listingDate":1287720000000,"exchange":"NASDAQ","adjPreClose":1.97,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AEGR\",,,,,undefined,":{"symbol":"AEGR","floatShares":14289727,"roa":"--","roe":"--","lyrEps":0,"shares":29545088,"dividePrice":0,"high":1.97,"amplitude":0,"preClose":1.97,"low":1.97,"week52Low":1.23,"pbRate":"--","week52High":10.85,"institutionHeld":0,"latestPrice":1.97,"eps":-5.97,"divideRate":0,"volume":0,"delay":0,"ttmEps":-5.97,"open":1.97,"prevYearClose":1.97},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.aegerion.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0293},{"period":"1month","weight":0.004},{"period":"3month","weight":-0.0583},{"period":"6month","weight":-0.0075},{"period":"1year","weight":0.1222},{"period":"ytd","weight":-0.033}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Aegerion Pharmaceuticals, Inc.是一家生物制药公司,致力于为那些衰弱的、患有致命罕见疾病的人开发新奇的,并且能够挽救生命的治疗方法并将其用于商业用途。公司的第一个产品JUXTAPID,在2012年12月21日得到了美国食品和药物管理局的营销批准,并作为对低脂肪饮食和其他降脂治疗的补充,包括低密度脂蛋白(LDL)血清法,如果可用,可降低纯合子家族性高胆固醇血症患者(HoFH)的低密度脂蛋白胆固醇(低密度)、总胆固醇(TC)、载脂蛋白B(B朊)和非高密度脂蛋白胆固醇(non-HDL-C)。2013年1月底,该公司在美国推出了JUXTAPID。在2012年的第一季度,它向欧洲药品局(EMA)提交了营销授权申请(MAA)请求批准上市,作为低脂肪饮食和其他降脂治疗的辅助,在用或是不用血清法的条件下减少患有血症的成年人体内的低密度脂蛋白、TC、载脂蛋白B和甘油三酯(TG)。公司于2005年2月在特拉华州法律下成立。","exchange":"NASDAQ","name":"Aegerion制药","nameEN":"Aegerion Pharmaceuticals"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"AEGR\",market:\"US\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AEGR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2016-11-03","symbol":"AEGR","fiscalQuarterEnding":null,"expectedEps":-0.67,"name":null,"time":"","type":"earning","dateTimestamp":1478145600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2016-08-09","symbol":"AEGR","fiscalQuarterEnding":null,"expectedEps":-0.25,"name":null,"time":"","type":"earning","dateTimestamp":1470715200000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2016-05-16","symbol":"AEGR","fiscalQuarterEnding":null,"expectedEps":-1.85,"name":null,"time":"盘后","type":"earning","dateTimestamp":1463371200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2016-02-25","symbol":"AEGR","fiscalQuarterEnding":null,"expectedEps":-0.97,"name":null,"time":"盘后","type":"earning","dateTimestamp":1456376400000,"reportTimeType":"post","actualEps":-0.89},{"market":"US","date":"2015-11-09","symbol":"AEGR","fiscalQuarterEnding":null,"expectedEps":-0.51,"name":null,"time":"盘后","type":"earning","dateTimestamp":1447045200000,"reportTimeType":"post","actualEps":0.07}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AEGR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AEGR\",market:\"US\",delay:false,,,undefined,":{}}}